Galectin Therapeutics Company Profile (NASDAQ:GALT)

About Galectin Therapeutics

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.94
  • 50 Day Moving Average: $1.7511
  • 200 Day Moving Average: $1.4970
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.22
  • P/E Growth: 0.0000
  • Market Cap: $53.00M
  • Outstanding Shares: 29,280,000
  • Beta: 1.4
Additional Links:
Companies Related to Galectin Therapeutics:

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (415.46% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016HC WainwrightReiterated RatingBuyView Rating Details
8/11/2016FBR & CoReiterated RatingBuy$12.00View Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyView Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Galectin Therapeutics (NASDAQ:GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015($0.17)($0.18)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20162($0.24)($0.22)($0.23)
Q3 20162($0.22)($0.20)($0.21)
Q4 20162($0.22)($0.20)($0.21)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.22)($0.22)($0.22)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline
4-traders.com logoGALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:GALT)
www.4-traders.com - August 25 at 10:09 AM
publicnow.com logoGalectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial (NASDAQ:GALT)
www.publicnow.com - August 25 at 10:09 AM
investornewswire.com logoWill Galectin Therapeutics Inc. (NASDAQ:GALT) Hit $12 Price Target? - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - August 20 at 9:21 AM
News IconGlobal NASH Market to Exhibit Remarkable 25.56% CAGR between 2020 and 2030 (NASDAQ:GALT)
reports.pr-inside.com - August 19 at 8:04 AM
finance.yahoo.com logoGALECTIN THERAPEUTICS INC Financials (NASDAQ:GALT)
finance.yahoo.com - August 17 at 5:23 PM
News IconStock Update on Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - August 12 at 8:09 AM
News IconGalectin Reports Second Quarter 2016 Financial Results And Provides Business Update (NASDAQ:GALT)
www.biospace.com - August 9 at 3:53 PM
reuters.com logoBRIEF-Galectin Therapeutics quarterly loss per share $0.20 (NASDAQ:GALT)
www.reuters.com - August 9 at 3:53 PM
streetinsider.com logoForm 8-K GALECTIN THERAPEUTICS For: Aug 09 (NASDAQ:GALT)
www.streetinsider.com - August 9 at 3:53 PM
twst.com logoGalectin Therapeutics Inc.: Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GALT)
www.twst.com - August 9 at 3:53 PM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:GALT)
biz.yahoo.com - August 9 at 8:04 AM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:GALT)
biz.yahoo.com - August 9 at 8:04 AM
finance.yahoo.com logoGalectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GALT)
finance.yahoo.com - August 9 at 8:04 AM
sbwire.com logoKidney Function Tests Market: Size, Share, Growth, Technology, Competition & Companies Involved by 2015 – 2021 (NASDAQ:GALT)
www.sbwire.com - August 8 at 5:17 PM
equities.com logoGalectin Therapeutics Inc. (GALT) is Trading Higher on Unusual Volume for August 02 - Equities.com (NASDAQ:GALT)
www.equities.com - August 4 at 5:29 PM
equities.com logoGalectin Therapeutics Inc. (GALT) Jumps 6.25% on August 02 - Equities.com (NASDAQ:GALT)
www.equities.com - August 4 at 8:04 AM
equities.com logoGalectin Therapeutics Inc. (GALT) Jumps 17.07% on August 01 - Equities.com (NASDAQ:GALT)
www.equities.com - August 2 at 5:25 PM
nasdaq.com logoGalectin Therapeutics (GALT) Jumps: Stock Rises 17.1% - Nasdaq (NASDAQ:GALT)
www.nasdaq.com - August 2 at 5:25 PM
streetinsider.com logoGalectin Therapeutics (GALT) Completes GR-MD-02 Phase 2 Patient Enrollment for NASH - StreetInsider.com (NASDAQ:GALT)
www.streetinsider.com - August 2 at 5:25 PM
zacks.com logoGalectin Therapeutics (GALT) Jumps: Stock Rises 17.1% (NASDAQ:GALT)
www.zacks.com - August 2 at 9:58 AM
streetinsider.com logoGalectin Therapeutics (GALT) Completes GR-MD-02 Phase 2 Patient Enrollment for NASH (NASDAQ:GALT)
www.streetinsider.com - August 2 at 9:58 AM
publicnow.com logoGalectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis (NASDAQ:GALT)
www.publicnow.com - August 2 at 9:58 AM
investornewswire.com logoCan Shares Of Galectin Therapeutics Inc. (NASDAQ:GALT) Hit $12? - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - July 30 at 8:01 AM
News IconNonalcoholic steatohepatitis market: major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa (NASDAQ:GALT)
www.medgadget.com - July 28 at 5:02 AM
investornewswire.com logoIs $12 Price Target Attainable For Galectin Therapeutics Inc. (NASDAQ:GALT)? - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - July 24 at 4:52 PM
News IconGalectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Increased By 6.77% - Consumer Eagle (NASDAQ:GALT)
www.consumereagle.com - July 22 at 8:02 AM
News IconShares Moving Down on the Week: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Engelwood Daily (NASDAQ:GALT)
www.engelwooddaily.com - July 16 at 4:58 PM
investornewswire.com logoStrong Sell Calls For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - July 16 at 8:33 AM
News IconDoes Galectin Therapeutics Inc Have Any Gas After Forming This Ascending Triangle Pattern? - Consumer Eagle (NASDAQ:GALT)
www.consumereagle.com - July 15 at 4:08 PM
News IconGalectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Decreased By 10.69% - Consumer Eagle (NASDAQ:GALT)
www.consumereagle.com - July 14 at 5:16 PM
fiscalstandard.com logoBroker Outlook For Galectin Therapeutics Inc. (GALT) - Fiscal Standard (NASDAQ:GALT)
www.fiscalstandard.com - July 14 at 8:30 AM
streetinsider.com logoGalectin Therapeutics (GALT) Announces Australian Notice of Patent for GR-MD-02 (NASDAQ:GALT)
www.streetinsider.com - July 13 at 5:29 PM
publicnow.com logoPeter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates (NASDAQ:GALT)
www.publicnow.com - July 13 at 9:08 AM
streetinsider.com logoGalectin Therapeutics (GALT) Announces Australian Notice of Patent for GR-MD-02 - StreetInsider.com (NASDAQ:GALT)
www.streetinsider.com - July 12 at 10:29 PM
publicnow.com logoGalectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis (NASDAQ:GALT)
www.publicnow.com - July 12 at 9:03 AM
News IconGalectin Therapeutics Inc (NASDAQ:GALT) Q1 2016 Sentiment - Consumer Eagle (NASDAQ:GALT)
www.consumereagle.com - July 11 at 5:11 PM
fiscalstandard.com logoGalectin Therapeutics Inc. (GALT) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:GALT)
www.fiscalstandard.com - July 10 at 9:36 AM
investornewswire.com logoIs $12 Within Reach For Galectin Therapeutics Inc. (NASDAQ:GALT)? - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - July 9 at 4:50 PM
News IconGalectin Therapeutics Incorporated (NASDAQ:GALT) Shorted Shares Decreased By 10.69% - Press Telegraph (NASDAQ:GALT)
presstelegraph.com - July 6 at 5:16 PM
News IconProtein target may block deadly arterial remodeling in pulmonary hypertension (NASDAQ:GALT)
medicalxpress.com - July 6 at 9:51 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Galectin Therapeutics Inc. (GALT) - Fiscal Standard (NASDAQ:GALT)
www.fiscalstandard.com - July 5 at 9:51 AM
investornewswire.com logoGalectin Therapeutics Inc. (NASDAQ:GALT) Expected to Reach Highs Of $12 - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - July 2 at 8:03 AM
News IconGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 10.69% of Their Shorts - Engelwood Daily (NASDAQ:GALT)
www.engelwooddaily.com - July 1 at 5:44 AM
equities.com logoGalectin Therapeutics Inc. (GALT) Jumps 5.37% on June 29 - Equities.com (NASDAQ:GALT)
www.equities.com - July 1 at 5:44 AM
ftsenews.co.uk logoNew Broker Ratings For Galectin Therapeutics Inc. (GALT) - FTSE News (NASDAQ:GALT)
www.ftsenews.co.uk - June 30 at 5:38 AM
News IconShare Volatility Check for: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Press Telegraph (NASDAQ:GALT)
presstelegraph.com - June 26 at 4:40 PM
investornewswire.com logoStrong Sell Calls Recommendations For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - June 26 at 4:40 PM
equities.com logoGalectin Therapeutics Inc. (GALT) Jumps 6.9% on June 24 - Equities.com (NASDAQ:GALT)
www.equities.com - June 26 at 4:40 PM
ftsenews.co.uk logoGalectin Therapeutics Inc. (GALT) Updated Price Targets - FTSE News (NASDAQ:GALT)
www.ftsenews.co.uk - June 23 at 8:04 AM
fiscalstandard.com logoThis Weeks Broker Views For Galectin Therapeutics Inc. (GALT) - Fiscal Standard (NASDAQ:GALT)
www.fiscalstandard.com - June 21 at 4:53 PM

Social

Galectin Therapeutics (NASDAQ:GALT) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff